



| | | |
|--|---------------------------------|-----------------------------------|
| FORM 1449* INFORMATION DISCLOSURE STATEMENT  IN AN APPLICATION (Use several sheets if necessary) | Docket Number: 11669.133USC1 | Application Number: 09/373,403 |
| | Applicant: ARATHOON ET AL. | |
| | Filing Date: AUGUST 12, 1999 | Group Art Unit: 1642 |
| | Customer No. 23552 | |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|--------------|------------|---------------|-------|----------|----------------------------|
| EXAMINER INITIAL | DOCUMENT NO. | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| AZH | 5,807,706 | 09/15/1998 | CARTER ET AL. | | | |
| AZH | 5,821,333 | 10/13/1998 | CARTER ET AL. | | | |
| | | | | | | |
| | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|--------------|------|---------|-------|----------|-------------|----|
| | DOCUMENT NO. | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | YES | NO |
| | | | | | | | |
| | | | | | | | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|--|--|---|
| AZH | | Bedzyk et al., "Active Site Structure and Antigen Binding Properties of Idiotypically Cross-reactive Anti-fluorescein Monoclonal Antibodies", <u>The Journal of Biological Chemistry</u> , 265(1):133-138 (1990) |
| | | Bryunck, A. et al., "Characterisation of a humanized bispecific monoclonal antibody for cancer therapy", <u>Br. J. Cancer</u> , 67:436-440 (1993) |
| | | Carter, P. et al., "Toward The Production of Bispecific Antibody Fragments for Clinical Applications", <u>J. Hematotherapy</u> , 4(5):463-470 (Oct. 1995) |
| | | Carter, P. et al., "Engineering antibodies for imaging and therapy", <u>Curr. Opin. Biotechnology</u> , 8(4):449-454 (Aug. 1997) |
| | | De Jonge, J. et al., "Production and Characterization of Bispecific Single-Chain Antibody Fragments", <u>Mol. Immunol.</u> , 32(17-18):1405-1412 (Dec. 1995) |
| | | Goddard et al., NCBI Genbank AF048774 (1998) |
| | | Goddard et al., NCBI Genbank AF048775 (1998) |
| | | Gulliver, G. et al., "Conversion of an Anti-single-stranded DNA Active Site to an Anti-fluorescein Active Site through Heavy Chain Complementarity Determining Region Transplantation", <u>The Journal of Biological Chemistry</u> , 269(11):7934-7940 (1994) |
| | | Gulliver, G. et al., "Effect of Transplantation of Antibody Heavy Chain Complementarity Determining Regions on Ligand Binding", <u>The Journal of Biological Chemistry</u> , 269(39):24040-24045 (Sept. 30, 1994) |
| | | Kriangkum, J. et al., "Bispecific and bifunctional single chain recombinant antibodies", <u>Biomolecular Engineering</u> , 18(1):31-40 (Aug. 2001) |

| | | | |
|----------|---|-----------------|----------|
| EXAMINER |  | DATE CONSIDERED | 9/4/2004 |
|----------|---|-----------------|----------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

| | | |
|---|---------------------------------|-----------------------------------|
| FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary) | Docket Number: 11669.133USC1 | Application Number: 09/373,403 |
| | Applicant: ARATHOON ET AL. | |
| | Filing Date: AUGUST 12, 1999 | Group Art Unit: 1642 |
| | Customer No. 23552 | |

| | | |
|------|--|--|
| 12/1 | | Mallender, W. et al., "Comparative Properties of the Single Chain Antibody and Fv Derivatives of mAb 4-4-20", <u>The Journal of Biological Chemistry</u> , 271(10):5338-5346 (March 8, 1996) |
| | | Mallender, W. et al., "Construction, Expression, and Activity of a Bivalent Bispecific Single-chain Antibody", <u>The Journal of Biological Chemistry</u> , 269(1):199-206 (Jan. 7, 1994) |
| | | Massino et al., "Quantitative analysis of the products of IgG chain recombination in hybrid hybridomas based on affinity chromatography and radioimmunoassay", <u>Journal of Immunological Methods</u> , 201:57-66 (1997) |
| | | Merchant et al., "An efficient route to human bispecific IgG", <u>Nature Biotechnology</u> , 16:677-681 (July 1998) |
| | | Muller, KM et al., "The first constant domain (C _H 1 and C _L) of an antibody used as heterodimerization domain for bispecific miniantibodies", <u>FEBS Letter</u> , 422(2):259-264 (January 30, 1998) |
| | | Muller, KM et al., "A dimeric bispecific miniantibody combines two specificities with avidity", <u>FEBS Letter</u> , 432(1-2):45-49 (July 31, 1998) |
| | | Pluckthun, A. et al., "New protein engineering approaches to multivalent and bispecific antibody fragments", <u>Immunotechnology</u> , 3(2):83-105 (June 1997) |
| | | Reddy, V. et al., "Production of Hybrids Secreting Bispecific Antibodies Recognising CEA and Doxorubicin", <u>Anticancer Research</u> , 13:2077-2084 (1993) |
| | | Rudikoff, S., "Single amino acid substitution altering antigen-binding specificity", <u>Immunology</u> , 79:1979-1983 (1982) |
| | | Segal, DM et al., "Introduction: bispecific antibodies", <u>J. Immunol. Methods</u> , 248(1-2):1-6 (Feb. 1, 2001) |
| | | Smith et al., "Variable Region Primary Structures of Monoclonal Anti-DNA Autoantibodies from NZB/NZW F ₁ Mice", <u>Molecular Immunology</u> , 27(5):463-470 (1990) |
| | | Tomlinson, IM et al., "The structural repertoire of the human V _K domain", <u>EMBO Journal</u> , 14(18):4628-4638 (Sept. 15, 1995) |
| | | Tomlinson, I. et al., "Methods for Generating Multivalent and Bispecific Antibody Fragments", <u>Methods Enzymol.</u> , 326:461-479 (2000) |
| | | Tso, JY et al., "Preparation of a Bispecific F(ab') ₂ Targeted to the Human IL-2 Receptor", <u>J. Hematotherapy</u> , 4(5):389-394 (Oct. 1995) |
| ✓ | | Vuillez, J. et al., "Two-Step Immunoscintigraphy for Non-Small-Cell Lung Cancer Staging Using a Bispecific Anti-CEA/Anti-Indium-DTPA Antibody and an Indium-111-Labeled DTPA Dimer", <u>The Journal of Nuclear Medicine</u> , 38(4):507-511 (April 1997) |

| | |
|---|---------------------------------|
| EXAMINER <i>Amie L. Hallen</i> | DATE CONSIDERED <i>9/4/2003</i> |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. | |